Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Intangibles (2020 - 2026)

InMed Pharmaceuticals has reported Intangibles over the past 5 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Intangibles fell 9.56% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 9.56%, while the annual FY2025 figure was $1.6 million, 44.64% down from the prior year.
  • Intangibles for Q4 2025 was $1.5 million at InMed Pharmaceuticals, down from $2.9 million in the prior quarter.
  • Over five years, Intangibles peaked at $2.9 million in Q4 2023 and troughed at $300000.0 in Q2 2023.
  • A 5-year average of $2.0 million and a median of $2.0 million in 2023 define the central range for Intangibles.
  • Biggest five-year swings in Intangibles: crashed 85.77% in 2023 and later surged 875.81% in 2024.
  • Year by year, Intangibles stood at $2.4 million in 2021, then fell by 15.57% to $2.0 million in 2022, then surged by 44.43% to $2.9 million in 2023, then crashed by 41.89% to $1.7 million in 2024, then dropped by 9.56% to $1.5 million in 2025.
  • Business Quant data shows Intangibles for INM at $1.5 million in Q4 2025, $2.9 million in Q3 2025, and $1.6 million in Q2 2025.